Clinical research
Treatment-naïve populations and faster first-patient-in
How large urban sites and motivated patients compress recruitment timelines versus saturated markets.
First-patient-in is the milestone that determines whether a trial timeline holds. Two structural factors move it earlier in the Philippines: population size and site saturation. (The 100M+ population figure cited elsewhere on this site is, like the cost figure, pending a cited source — flagged here rather than restated as settled.)
Why enrollment moves faster here
- A large, English-speaking population reduces translation and back-translation overhead on consent and patient materials.
- A largely treatment-naïve patient pool means less competition from prior or concurrent trials for the same eligibility criteria.
- Dense urban site clusters put a realistic enrollment target within a short referral radius, rather than spread across a wide site network.
What slows enrollment down elsewhere
Sponsors moving volume into Southeast Asia are usually leaving a saturated site network behind — the same academic centers running five competing protocols for the same indication. That's the comparison this figure is measured against, not enrollment in the abstract.
What to verify before committing volume
Ask for realistic screen-failure and consent-withdrawal rates for your specific indication at the sites under consideration, not just the topline population figure. A large population does not by itself guarantee eligible, retainable patients for a narrow protocol.